Primary familial polycythemia due to EPO receptor mutation: genes and variants
Explore variant evidence for Primary familial polycythemia due to EPO receptor mutation across 3 analyzed proteins (SH2B3, HBA1, JAK2). Linked ClinVar records include 1 pathogenic or likely pathogenic variants, 4 variants of uncertain significance and 2 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Counts refer to the selected disease label.
Data updated 2026-10-21. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Primary familial polycythemia due to EPO receptor mutation
SH2B3: SH2B adapter protein 3
It restrains cytokine and growth-factor signaling in hematopoietic cells, including JAK-STAT pathways controlling blood-cell production. Loss-of-function variants can increase blood-cell proliferation and predispose to myeloproliferative neoplasms, while common variants influence autoimmune and hematologic traits.
1 ClinVar pathogenic / likely pathogenic and 3 uncertain variants in SH2B3 have source records linked to Primary familial polycythemia due to EPO receptor mutation. Association strength is not clinical gene validity.
HBA1: Hemoglobin subunit alpha
It contributes alpha-globin chains that pair with beta-like globins to carry oxygen in red blood cells. Deletion or inactivation reduces alpha-globin production and causes alpha-thalassemia, with severity determined by the number and function of affected alpha-globin genes.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in HBA1 have source records linked to Primary familial polycythemia due to EPO receptor mutation. Association strength is not clinical gene validity.
JAK2: Tyrosine-protein kinase JAK2
It transmits signals from erythropoietin, thrombopoietin, growth hormone, and other cytokine receptors into STAT-dependent transcription. The V617F gain-of-function variant is a major driver of polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
0 ClinVar pathogenic / likely pathogenic and 3 uncertain variants in JAK2 have source records linked to Primary familial polycythemia due to EPO receptor mutation. Association strength is not clinical gene validity.
ClinVar pathogenic and likely pathogenic variants linked to Primary familial polycythemia due to EPO receptor mutation
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| SH2B3 M1V | 1 | Pathogenic / likely pathogenic (★) |
Diseases related to Primary familial polycythemia due to EPO receptor mutation
- Thrombocythemia, also linked to JAK2 and SH2B3
- Primary myelofibrosis, also linked to JAK2 and SH2B3
- Familial erythrocytosis, also linked to HBA1
- Acute myeloid leukemia, also linked to JAK2
- Heinz body anemia, also linked to HBA1
- Alpha Thalassemia, also linked to HBA1
- Hemoglobin M disease, also linked to HBA1
- Crohn disease, also linked to JAK2
- Essential thrombocythemia, also linked to JAK2
- Type 1 diabetes mellitus, also linked to SH2B3
- Hypothyroidism, also linked to SH2B3
- Inflammatory bowel disease, also linked to JAK2
Frequently asked questions
Which genes have records linked to Primary familial polycythemia due to EPO receptor mutation?
This view contains 3 analyzed proteins: SH2B3, HBA1, JAK2. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 1 pathogenic or likely pathogenic variants, 4 variants of uncertain significance and 2 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 25 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center